ASCO 2025

ASCO 2025

Innovative oncology discussion featuring medical experts sharing insights on cancer treatment strategies at OncUpdates conference.

ASCO 2025

06/16/2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MDEstelamari Rodriguez, MD, MPHHelena Yu, MD
Expert medical panel discussion on cancer updates and new treatment strategies at OncUpdates.

ASCO 2025

06/16/2025

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MDJoshua Sabari, MD
Doctor and patient discussion about cancer treatment at OncUpdates conference, emphasizing oncology care and medical research.

ASCO 2025

06/16/2025

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MD
Frontline treatment for metastatic EGFR-mutated NSCLC discussed by leading oncologists at OncUpdates, featuring Dr. Susan Scott, Dr. Rohit Gosain, and Dr. Rahul Gosain.

ASCO 2025

06/16/2025

Frontline Treatment for Metastatic EGFR-Mutated NSCLC

Susan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD
Mariposa: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC - Oncology research featuring leading doctors discussing advanced lung cancer treatment options and targeted therapies.

ASCO 2025

06/15/2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MDSusan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD